Have you ever thought that the next medical breakthrough may not come from a lab?
Yes, it might arrive as a smarter algorithm.
In 2024, the global AI-healthcare market reached USD 26.6 billion, with projections toward USD 110 billion by 2030, a growth curve of nearly 39% annually (Markets & Markets).
The acceleration isn’t just “more AI.”
It’s AI connecting what used to live apart: clinical imaging, genomics, lab data, and doctor notes.
These multimodal systems detect patterns invisible to humans, and they’re starting to make recommendations that are shifting how medicine works.
The regulatory pulse
By mid-2024, the FDA had cleared almost 950 AI/ML medical devices, most of which were in radiology and cardiovascular diagnostics (MedTech Dive).
The agency’s new guidance allows adaptive models to update without full re-approval, so we are facing a quiet revolution in how algorithms evolve once deployed.
Breakthrough-level AI tools are also gaining traction, from digital pathology to predictive imaging.
The direction is clear: health AI will operate more like living software than static machines.
“Every health-AI system runs on compute.” Dr. Sarah Gebauer.
Stock spotlight – NVIDIA (NVDA)
NVIDIA still owns the lion’s share of GPU infrastructure, making it the tollbooth for the entire AI-medicine economy.
Hospitals may never buy GPUs directly, but every scan analyzed by AI ultimately pays that rent upstream.
Startup watch – Qure.AI (QURE)
India-based Qure.AI processes ~15 million patient scans yearly across Asia, Africa, and Latin America, growing its revenue 60%-70% year over year (Reuters).
Its technology detects tuberculosis, lung disease, and stroke risk… and the firm is preparing a US expansion.
Accessible diagnostics at a global scale could redefine healthcare in emerging markets.
Why does it matter?
The opportunity isn’t simply “AI in health.”
It’s about which AI frameworks hospitals trust.
True defensibility lies in access to clinical data, compute scaling, and continuous validation.
Roughly 4.8% of cleared AI devices have faced recalls, reminding investors that transparency, bias testing, and patient-group reliability remain critical (RAPS).
Reader Bonus: Download your free guide
Get “12 AI + Health Stocks to Watch in 2025”: early-stage names, compute dependencies, and risk profiles.
Rabbt Founder Membership Pre-Signup! (coming soon)
Only 97 Lifetime Founder slots remain. Founders receive:
- Full Lifetime Access to the Rabbt Intelligence Dashboard
- Early access to Genesis Core AI
- Entry to our private community + live briefings
Talk soon,
Rabbt Dispatch
Frontline intelligence for tech-driven investors. © 2025
This publication is for educational purposes only and is not financial advice.